We can’t show the full text here under this license.
How ALKBH5 helps colorectal cancer resist oxaliplatin by changing NPC2 mRNA
Updated
Abstract
High expression is associated with oxaliplatin resistance and poor prognosis in colorectal cancer patients.
- Oxaliplatin is a crucial chemotherapy drug for colorectal cancer but resistance to it often develops.
- Bioinformatics analysis identified a link between elevated NPC2 levels and decreased treatment effectiveness.
- NPC2 expression is particularly high in metastatic colorectal cancer tissues.
- In oxaliplatin-resistant colorectal cancer cells, levels of the mA demethylase ALKBH5 are significantly increased.
- ALKBH5 enhances the stability of NPC2 mRNA through a specific process, contributing to drug resistance.
- Inhibiting NPC2 or ALKBH5 may help restore sensitivity to oxaliplatin in resistant colorectal cancer cells.
Simplified
Key numbers
1.679
Increase in expression
Hazard ratio for overall survival based on expression.
4 of 4
Oxaliplatin resistance in CRC cells
All oxaliplatin-resistant CRC cell lines exhibited elevated levels.